CSIMarket Company Name, Ticker, Suppliers, else..
 
Avid Bioservices Inc   (NASDAQ: CDMO)
Other Ticker:  
 
 
Price: $12.3900 $0.01 0.081%
Day's High: $12.41 Week Perf: -0.32 %
Day's Low: $ 12.37 30 Day Perf: 0.24 %
Volume (M): 1,635 52 Wk High: $ 12.48
Volume (M$): $ 20,260 52 Wk Avg: $9.29
Open: $12.38 52 Wk Low: $5.90



 Market Capitalization (Millions $) 791
 Shares Outstanding (Millions) 64
 Employees 371
 Revenues (TTM) (Millions $) 151
 Net Income (TTM) (Millions $) -152
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 15

Avid Bioservices Inc
Avid Bioservices Inc is a biopharmaceutical company based in California. They specialize in providing contract manufacturing services for the development and production of biologics, such as monoclonal antibodies and recombinant proteins. Avid Bioservices has state-of-the-art facilities and a team of experienced professionals to support their clients' drug development programs. They have a strong track record of successfully delivering high-quality products to the biotechnology and pharmaceutical industries.


   Company Address: 14191 Myford Road Tustin 92780 CA
   Company Phone Number: 508-6100   Stock Exchange / Ticker: NASDAQ CDMO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BPMC        6.47% 
CTLT        0.38% 
SRPT   -0.36%    
STOK        4.93% 
VERV        11.64% 
WVE   -2.48%    
• View Complete Report
   



Merger and Acquisition

Avid Bioservices Files Investor Presentation Highlighting Value-Maximizing Transaction with GHO and Ampersand,

Published Wed, Jan 8 2025 10:15 PM UTC

Avid Urges Stockholders to Vote FOR the Pending Transaction TODAYIn a decisive move within the biopharmaceutical sector, Avid Bioservices Inc. (NASDAQ: CDMO) is urging its stockholders to vote in favor of the upcoming acquisition involving GHO Capital and Ampersand Capital Partners. With the expiration of the Hart-Scott-Rodino (HSR) waiting period on December 30, 2024, the c...
Merger and Acquisition

Avid Bioservices Surges Forward as Hart-Scott-Rodino Waiting Period Expires in GHO and Ampersand Acquisition

Published Mon, Dec 30 2024 2:00 PM UTC

On December 30, 2024, Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated contract development and manufacturing organization (CDMO) specializing in biologics, heralded an important milestone in its proposed acquisition by GHO Capital Partners LLP and Ampersand Capital Partners. The expiration of the Hart-Scott-Rodino (HSR) Antitrust Improvements Act waiting period marks a si...
Stock Market Announcement

Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing Transaction

Published Wed, Dec 18 2024 9:35 PM UTC

Avid Bioservices Advocates for Shareholder Approval of Value Maximizing Transaction: What It Means for InvestorsIn a recent development, Avid Bioservices Inc. (NASDAQ: CDMO) has taken a significant step towards enhancing shareholder value. The company has formally recommended that stockholders vote in favor of a value-maximizing transaction, alongside filing its definitive ...
Merger and Acquisition

Avid Bioservices Set for Transformation with $1.1 Billion Buyout by GHO Capital and Ampersand

Published Wed, Nov 6 2024 11:04 PM UTC

IntroductionIn a significant move that could reshape the landscape of biologics contract development and manufacturing, Avid Bioservices, Inc. (NASDAQ: CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners for approximately $1.1 billion. This all-cash transaction marks a pivotal moment for the Tustin, California-based company, known for its ...
Avid Bioservices Inc

2. Avid Bioservices Inc Faces Financial Pressures Amid Growth in Contract Manufacturing Sector

Avid Bioservices Inc is a biotechnology company that specializes in providing contract manufacturing and development services to the biopharmaceutical industry. The company's revenue for the fourth quarter of 2024 increased by 11.501% compared to the same period the previous year, reaching $43.50 million. However, despite the increase in revenue, Avid Bioservices Inc reported a deficit per share of $-1.94 for the same period.
CDMOs, or Contract Development and Manufacturing Organizations, have been performing well in the pharmaceutical industry, with many companies facing challenges such as declining businesses and shrinking revenue. Avid Bioservices Inc stands out in this sector, with a significant increase in revenue and net loss for the fourth quarter of 2024. The company recorded a net deficit of $-123.104 million for the period, compared to $-0.610 million in the previous year.






Avid Bioservices Inc's Segments
Manufacturing Revenues    81.46 % of total Revenue
Process Development Revenues    18.54 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com